何雅億 副主任医师，副教授
硕士招生类型：学术型
硕士招生专业：肿瘤学
博士招生类型：学术型；专业型
博士招生专业：肿瘤学
所在院系：附属肺科医院
联系方式：**@qq.com
课题组链接：
研究方向
主要任职
科研业绩

肺癌的临床、转化及基础研究。肺癌的靶向治疗、免疫治疗，以及早期诊断和转移机制探索。肺癌诊治的新材料研发。Clinical, transformation and basic research of lung cancer. Exploring targeted therapy, immunotherapy, and early diagnosis and metastasis mechanisms of lung cancer. Research and development of new materials for lung cancer diagnosis and treatment.
副主任医师，副教授，博士研究生导师；上海市浦江人才；上海市青年拔尖人才；CSCO非小细胞肺癌专委会秘书；CSCO青年专家委员会委员；SCI期刊Translational Lung Cancer Research编委Associate chief physician, associate professor, doctoral supervisor；Shanghai Pujiang Project；
采用C-T-B-C教学模式，指导学生完成多项肺癌基础及转化研究，发表多篇高水平论文；临床工作中，每年诊治患者2000余例，其中新诊肺癌患者600余例。每年完成肺穿刺500余例，气管镜200余例；在临床工作的同时，主持并参与多项基金及课题；2017年获得上海市浦江人才，2019年获得上海市青年拔尖人才称号；进行肺癌转化相关研究，成果多次在美国临床肿瘤学会（ASCO）、欧洲临床肿瘤学会（ESMO）、世界肺癌大会（WCLC）、日本肺癌学会年会（JLCS）等国际会议上进行口头汇报及壁报展示，并获得2016年ESMO、2019年ESMO ASIA和2019年JLCS的Travel Grant奖项；参与了多项肺癌靶向治疗、免疫治疗等相关的多中心、III期临床研究；
目前共发表论文75篇，以第一作者/共第一、通讯/共通讯作者身份发表论文60篇，总IF 504.568，总引用次数704次，研究涵盖了肺癌分子靶向治疗，免疫治疗及早期诊断等方面；以秘书身份参与2019年CSCO原发性肺癌诊疗指南及2020年CSCO非小细胞肺癌诊疗指南编写工作。以编委身份参与编撰2019年中国非小细胞肺癌免疫检查点抑制剂治疗专家共识及晚期非小细胞肺癌抗血管生成药物治疗的中国专家共识，以第一发明人身份申请国家专利6项；
现任CSCO非小细胞肺癌专委会秘书，中国抗癌协会肿瘤药物临床研究专委会委员，CSCO青年专家委员会委员。CSCO、ASCO、ESMO及IASLC会员。担任SCI期刊Translational Lung Cancer Research编委。担任SCI期刊Translational Lung Cancer Research编委，以及OncoTargets and Therapy、Medical Science Monitor等SCI杂志审稿人。
Dr. He use C-T-B-C teaching mode to guide students to complete the basic and translational research of lung cancer, and published many high-level manuscripts； In clinical work, more than 2000 patients are diagnosed and treated by Dr. He every year, including more than 600 newly diagnosed lung cancer patients. More than 500 cases of lung puncture and more than 200 cases of tracheoscope were done by Dr. He every year； Dr. He was in charge of or participated in a number of projects；
Dr. He was awarded Shanghai Pujiang Project in 2017 and Shanghai Top Young Talent in 2019；
Dr. He has carried out researches on lung cancer translation research. His achievements have been presented at international conferences such as American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), World Lung Cancer Congress (WCLC), and Annual Meeting of Japan Lung Cancer Society (JLCS). Dr. He has won the travel grant awards of ESMO 2016, ESMO Asia 2019 and JLCS 2019； Dr. He has participated in a number of multi center and phase III clinical studies related to lung cancer targeted therapy and immunotherapy； At present, 75 manuscripts have been published, and 60 papers have been published as the first author/CO-first author and correspondence/CO-correspondent author by Dr. He. The total IF is 504.568 and the total number of citations is 704. The researches cover molecular targeted therapy, immunotherapy and early diagnosis of lung cancer；
Dr. He participated in CSCO guidelines for diagnosis and treatment of primary lung cancer in 2019 and non-small cell lung cancer in 2020 (secretary). As a member of the editorial board, Dr. He participated in the compilation of the experts consensus of the treatment of immune checkpoints inhibitor for non-small cell lung cancer in China in 2019 and the Chinese expert consensus on the treatment of antiangiogenic drugs for advanced non-small cell lung cancer in 2019, and applied for 6 national patents as the first inventor；
Dr. He is currently secretary of CSCO non-small cell lung cancer committee, member of cancer drug clinical research committee of China Anti Cancer Association, and member of CSCO youth expert committee. CSCO, ASCO, ESMO and IASLC members. Dr. He served as the editorial board of Translational Lung Cancer Research and reviewer of Oncotargets and Therapy, Medical Science Monitor and other SCI journals.